Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
03 nov 2006 - 15:01
Statutaire naam
Crucell N.V.
Titel
The Netherlands Invest €18.4 Million to Develop Better Vaccines to Fight Raging TB Pandemic
Bericht
Aeras to Partner with Crucell, KNCV Tuberculosis Foundation and other Top Dutch Scientific Organisations
(The Netherlands, Nov. 3, 2006) As extreme forms of drug resistant tuberculosis threaten to make the TB pandemic even worse, Dutch funding and scientific expertise are playing a critical role in the development of new, more effective TB vaccines.
The Dutch Ministry of Foreign Affairs (DGIS) made an €18.4 million, four-year investment in Aeras Global TB Vaccine Foundation, a Product Development Partnership (PDP) that is collaborating with Crucell N.V., KNCV Tuberculosis Foundation, Netherlands Cancer Institute (NKI-AVI) and other Dutch organizations to develop new TB vaccines.
“Vaccines have wiped out smallpox and nearly eliminated polio. A vaccine for TB could reverse the tide of the TB pandemic and save millions of lives,” said Dr. Jerald Sadoff, President and CEO of Aeras Global TB Vaccine Foundation. “The Netherlands has shown great global leadership to develop new solutions to global health problems that burden developing countries. DGIS’ strong financial support for Aeras’ work and the Netherlands’ first-rate scientific expertise will both speed development of a new vaccine and help mobilize commitments from other donor countries.”
TB kills nearly 2 million people a year, TB/HIV co-infection is worsening the pandemic, and recently-discovered extremely drug resistant TB (XDR-B), is on the rise, particularly in Eastern Europe and countries on the Baltic Sea. Today’s TB vaccine is more than 85 years old, provides only marginal protection for infants and provides very little, if any, protection beyond childhood. Aeras’ goal is to develop new, safe and effective vaccine regimens that prevent TB in children, adolescents and adults, targeted for licensure in 7-10 years.
Datum laatste update: 24 december 2025